FSN Ref: FSN_0002_Osypka_ FSCA _NCR_155_2022

FSCA Ref: FSCA_0002_NCR_155_2022



Date: 22.11.2022

Urgent Field Safety Notice (FSN)

Recall

regarding

VACSIII 22x40 Percutaneous Transluminal Valvuloplasty Catheter, YA 32240, LOT P351784-06 VACSIII 24x40 Percutaneous Transluminal Valvuloplasty Catheter, YA 32440, LOT P351384-05

Attn: to be completed by Sales

Dear Customer.

According to our records, you have received products from one or both of the above mentioned batches P351784-06 and P351384-05.

Based on customer feedback, we have determined that a mix-up occurred during the labelling process for these products. This means that the products labelled as VACSIII catheter size 22x40, item number YA32240 of batch P351784-06 actually contain VACSIII catheter size 24x40, item number YA 32440 of batch P351384 and vice versa.

Only products from the two mentioned batches are affected. Based on an internal check, we can exclude the possibility that other products are involved.

We therefore inform you as a precaution and ask for your cooperation in identifying and returning the products from the affected batches delivered to you. Please use the attached form for your response.

The following pages of this letter contain further information on the affected products, the possible risks for patients/users and the measures to be taken on your part.

The Federal Institute for Drugs and Medical Devices (BfArM) has been informed.

If you have any queries, please contact our Safety Officer/ PRRC Vigilance at the following contact details:

Dr. Nicola Osypka Earl-H.-Wood-Str. 1 79618 Rheinfelden Germany

Tel: +49-(0)7623-7405-0 E-mail: vigilance@osypka.de

Thank you in advance for your cooperation.

Yours sincerely,

FSN Ref: FSN_0002_Osypka_FSCA_NCR_155_2022

FSCA Ref: FSCA_0002_NCR_155_2022



Ilse Karin Kastner VP Sales

OSYPKA AG Medizintechnik

Earl-H.-Wood-Str. 1 79618 Rheinfelden Deutschland FSN Ref: FSN_0002_Osypka_ FSCA _NCR_155_2022

FSCA Ref: FSCA_0002_NCR_155_2022



Urgent Field Safety Notice (FSN)

VACSIII 22x40 Percutaneous Transluminal Valvuloplasty Catheter, YA 32240, LOT P351784-06 VACSIII 24x40 Percutaneous Transluminal Valvuloplasty Catheter, YA 32440, LOT P351384-05

During a review of the manufacturing records for a claim, it was noted that balloon size 22 had a diameter 2mm larger than indicated on the label, and conversely, balloon size 24 had a diameter 2mm smaller. The laser print on the Y-piece corresponds to the actual balloon size in both cases.

		1. Information on Affected Devices*
1.	2	Device Type(s)*
	Percut	aneous Transluminal Valvuloplasty Catheter
1.	3	Commercial name(s
	PTV Ba	alloon Dilatation Catheter
1.	4	Unique Device Identifier(s) (UDI-DI)
	K.A.	
1.	5	Primary clinical purpose of device(s)*
	Valvulo	pplasty
1.	6	Device Model/Catalogue/part number(s)*
	YA322	40 und YA32440
1.	7	Software version
	K.A.	
1.	8	Affected serial or lot number range
	P35178	34-06 und P351384-05
1.	9	Associated devices
	K.A.	

	2 Reason for Field Safety Notice (FSN)*
2.	2 Description of the product problem*
	The diameter of the balloon is larger or smaller than specified
2.	3 Hazard giving rise to the FSCA/FSN*
	A hazard is to be expected if the product is used according to the Instructions for Use (IFU), as the mounted balloon portion does not correspond to the indication on the package labels. If the discrepancy is not noticed during the preparation for surgery (comparison of label/Y-piece on the product), it may lead to the use of too large a catheter with possible fatal consequences
2.	4 Probability of problem arising

FSN Ref: FSN_0002_Osypka_FSCA_NCR_155_2022

FSCA Ref: FSCA_0002_NCR_155_2022



	Occasi	onally
2.	5	Predicted risk to patient/users
	Risk o	f fatal consequences when using a catheter size that is too large if the different
	design	ation on the label and Y-piece is not noticed.
2.	6	Further information to help characterise the problem
	K.A.	
2.	7	Background on Issue
	In a co	mplaint report, it was noted during the preparation for surgery that the size information
	for the	balloon on the Y-piece and the packaging label were different.
2.	8	Other information relevant to FSCA/FSN
	K.A.	

	3 Type of Action to mitigate the risk*				
3.	1	Action To Be Taken by	the User*		
		oxtimes Identify Device $oxtimes$	Quarantine Device	□ Return Device □	☐ Destroy Device
		_			
		☐ On-site device modif	fication/inspection		
		☐ Follow patient mana	gement recommendation	ons	
		☐ Take note of amend	ment/reinforcement of	Instructions For Use (15	EL 1)
			ment/rennorcement of	instructions for ose (ii	O)
		□ Other □	None		
3.	2	Particular consideration	ns for: VACSII 22x40	Cardiac valvuloplasty o	atheter
		·	or review of patients' p	revious results recomn	nended?
		No			
3.	3	Is customer Reply Requ	ired? *	Υ	es
	(If	yes, form attached speci)	
3.	4	Action Being Taken by	the Manufacturer		
		□ Product Removal	☐ On-site device m	odification/inspection	
		☐ Software upgrade	☐ IFU or labelling cl	nange	
		⊠ Other	☐ None		
		△ Other	□ NOTIC		
				- !	
		Provide further details of	of the action(s) identified		
		Provide further details of completely checked. No			
3	5	Provide further details of completely checked. No batches.	of the action(s) identified to other similar products	are affected. The erro	
3	5	Provide further details of completely checked. No batches. By when should the act	of the action(s) identified to other similar products	are affected. The erro	
3	5	Provide further details of completely checked. No batches. By when should the act completed?	of the action(s) identified to other similar products	are affected. The error	
		Provide further details of completely checked. No batches. By when should the act completed?	of the action(s) identified to other similar products	are affected. The error	is limited to the two
		Provide further details of completely checked. No batches. By when should the act completed? Is the FSN required to buser?	of the action(s) identified to other similar products	mpleted patient /lay	r is limited to the two

FSN Ref: FSN_0002_Osypka_ FSCA _NCR_155_2022

FSCA Ref: FSCA_0002_NCR_155_2022



No	

		4. ger	neral information*		
4.	2	FSN-Typ*	New		
4.	3	For updated FSN, reference number and date of previous FSN	N/A		
4.	4	For Updated FSN, key new information	n as follows:		
		N/A			
4.	5	Further advice or information already expected in follow-up FSN? *	No		
	6				
4.		N/A			
4.	7	Anticipated timescale for follow-up FSN	N/A		
4.	8	Manufacturer information			
	(Fc	or contact details of local representative			
		a. Company Name	OSYPKA AG		
		b. Address	Earl-HWood-Str. 1		
			79618 Rheinfelden		
		c. Website address	www.osypka.de		
4.	9 The Competent (Regulatory) Authority of your country has been informed about communication to customers. YES Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) Germany		ity of your country has been informed about this		
4.	10	List of attachments/appendices:	No Attachment		
4.	_	Name/Unterschrift	Dr. Nicola Osypka, PRRC		

Transmission of this Field Safety Notice

This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.

FSN Ref: FSN_0002_Osypka_NCR_155_2022 FSCA Ref: FSCA_0002_NCR_155_2022



Field Safety Notice (FSN)

Distributor/Importer Reply Form

1. Field Safety Notice (FSN) information			
FSN Reference number*	FSN_0002_Osypka_ NCR_155_2022		
FSN Date*	22.11.2022		
Product/ Device name*	VACS III 22x40 Cardiac valvuloplasty catheter VACSIII 24x40 Cardiac valvuloplasty catheter		
Product Code(s)	YA32240 + YA32440		
Lot/Serial Number (s)	P351784-06 + P351384-05		

2. Distributor/Importer Details	
Company Name*	Pre-filled by manufacturer
Account Number	Pre-filled by manufacturer
Address*	Pre-filled by manufacturer
Shipping address if different to above	Pre-filled by manufacturer
Contact Name*	Pre-filled by manufacturer
Title or Function	Pre-filled by manufacturer
Telephone number*	Pre-filled by manufacturer
Email*	Pre-filled by manufacturer

3. c	. customer action on behalf of the health organisation			
	I acknowledge receipt of the field safety notice and confirm that I have read and understood its contents.		ed by customer	
	I have carried out all the measures required by the FSN.	Need to be filled by customer		
	The information and necessary measures were brought to the attention of all relevant users and implemented.	Need to be fille	ed by customer	
	I have returned the products concerned - indicate the number of products returned and the date of return.	Amount:	Lot/Serial nnumber: P351784-06 Lot/Serial nnumber: P351384-05	Date of return: (DD/MM/YY) Date of return: (DD/MM/YYY)
		Comments:	,	,
	I have destroyed the affected products - enter	Amount:	Lot/Serial nnumber: P351784-06	

FSN Ref: FSN_0002_Osypka_NCR_155_2022 FSCA Ref: FSCA_0002_NCR_155_2022



	the number of products destroyed and the date of completion.	Amount:	Lot/Serial nnumber: P351384-05
	'	Comments.	
	There are no affected products available for return/destruction.	Need to be filled by customer	
	Other action (define):	Need to be filled by customer	
	I do not have any affected products.	Need to be filled by customer	
	I have a question, please contact me (e.g. need to replace the product).	The customer enters his contact details, if different from those above, and a brief description of his concern Need to be filled by customer	
Name in block capitals		Please enter your name here	
Signature			
Date		Need to be filled by customer	

4. Return acknowledgement to Sender	Mrs. Ilse Kastner
Email	a.kaister@osypka.de, s.sommer@osypka.de
Distributor/Importer Helpline	+497623 7405209
Postal Address	OSYPKA AG
	Medizintechnik
	Earl-HWood-Str. 1
	79618 Rheinfelden
	Deutschland / Germany
Web Portal	www.osypka.de
Deadline for returning the	December, 16 th , 2022
Distributor/Importer reply form	

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.